Merck Announces Top-Line Results From Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination Of Doravirine/Islatravir For Treatment Of People With HIV-1 Infection; Week 48 Data Met Safety And Efficacy Endpoints